Latest Anthrax Stories
NEW ROCHELLE, N.Y., Sept. 28 /PRNewswire/ -- Jagermeister has added top talent to the already hard-hitting 2010 Jagermeister Fall Music Tour. Jim Florentine of VH1's "That Metal Show" is set to emcee North America's biggest thrash tour in 20 years; the 1991 original "Clash of the Titans" lineup - Slayer, Megadeth and Anthrax. The brand's 17th Music Tour will feature complete performances of Slayer's much lauded Seasons in the Abyss Album from 1990, Megadeth's landmark 1990 album Rust in...
An antibacterial enzyme found in human tears and other body fluids could be applied to certain foods for protection against intentional contamination with anthrax, scientists reported today at the 240th National Meeting of the American Chemical Society (ACS)."Data from this study could be used in developing safer foods for human consumption," said Saeed A. Khan, Ph.D. "The data from our study shows that lysozyme application has the potential to eliminate anthrax producing...
CHICAGO, Aug. 24 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced plans to seek additional government funding for development of its novel, once-daily antibiotic, Restanza(TM) (cethromycin) based on a new, high-profile report from the Department of Health and...
NEW ROCHELLE, N.Y., Aug. 17 /PRNewswire/ -- Jagermeister, the brand known for decades of involvement with rock and metal bands, continues to own the concert circuit with the announcement of the 2010 Fall Jagermeister Music Tour, North America's biggest thrash tour in 20 years with the 1991 original "Clash of the Titans" lineup - Slayer, Megadeth and Anthrax. The brand's 17th Music Tour will bring three of the hardest hitting metal bands in the world to one stage and will feature complete...
CHICAGO, Aug. 5 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has been featured as a special stock pick for August, 2010 by "The KonLin Letter," a 27 year old independent, financial newsletter (www.konlin.com). This is an unsolicited and...
PINE BROOK, N.J., Aug. 4 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company, announced today that it has been awarded a second contract year of funding valued at $40.6 million for the advanced development of Anthim for the prevention and treatment of anthrax infection following a biowarfare attack. This funding is in addition to $16.8 million already received under this contract and is part of a potential five year contract award totaling up to...
SAN DIEGO, Aug. 3 /PRNewswire/ -- Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA) has awarded Pfenex a contract providing for up to a total of $18.8 million in funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government. The contract will support the development of a robust Pfenex Expression Technology(TM)...
PINE BROOK, N.J. and BASEL, Switzerland, July 15 /PRNewswire/ -- Elusys Therapeutics and Lonza today announced an agreement for the scale-up and commercial production of Anthim, a therapeutic monoclonal antibody in late-stage development for the treatment of inhaled anthrax. Under the new contract, Lonza will provide process scale-up, technology transfer, validation, and commercial manufacturing at one of its facilities in the USA. The manufacturing process for Anthim was optimized for full...
ANNAPOLIS, Md., July 15 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced results from a New Zealand White Rabbit study showing that its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine was more immunogenic than a liquid formulation of rPA vaccine and produced a robust response with only 2 doses. The data were presented in a poster presentation...
CHICAGO, July 8 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from preclinical toxicology and pharmacokinetic studies of an intravenous (IV) formulation of its novel antibiotic, Restanza(TM) that support its use in a hospital setting....
Latest Anthrax Reference Libraries
Bacillus anthracis is a Gram-positive spore-forming, rod-shaped bacterium, with a width of 1-1.2µm and a length of 3-5µm. It can grow in aerobic or anaerobic conditions. It is the only known bacterium to synthesize a protein capsule and the only pathogenic bacterium to carry its own adenylyl cyclase virulence factor. They form oval spores located centrally in a non-swollen sporangium. These spores are highly resilient and can survive extreme temperatures, low-nutrient environments, and...
